Ovarian Cancer

FDA grants fast track designation to a PARG inhibitor, ETX-19477, for the treatment of BRCA-mutated, platinum-resistant HGSOC.

The FDA approved subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma and granted a pair of breakthrough therapy designations.

The FDA has granted breakthrough therapy designation to JSKN003 in HER2+ platinum-resistant ovarian cancer.

Alexander B. Olawaiye, MD, spotlights this phase 2 study evaluating bevacizumab plus relacorilant and nab-paclitaxel in platinum-resistant ovarian cancer.

Antonio Gonzalez-Martin, MD, discusses the key safety findings from the NAPISTAR1-01 trial of TUB-040 in ovarian cancer.

Antonio González-Martín, MD, PhD, discusses data for TUB-040 in platinum-resistant ovarian cancer and how it stacks up against other ADCs.

Fuzuloparib extended PFS vs placebo regardless of the addition of apatinib in newly diagnosed advanced ovarian cancer.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

Antonio Gonzalez-Martin, MD, discusses the design of the NAPISTAR1-01 trial of TUB-040 in ovarian cancer.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

Maurie Markman, MD, discusses the evolving role of measurements in cancer care.

Antonio Gonzalez-Martin, MD, discusses the rationale for targeting NaPi2b in ovarian cancer.

Initial activity and safety with the investigational ADC TUB-040 in ovarian cancer have renewed interest in NaPi2b as a target for ADC development.

The top 5 OncLive TV videos of the week cover insights in breast cancer and ovarian cancer.

Nicoletta Colombo, MD, PhD, discusses the rationale for evaluating pembrolizumab plus weekly paclitaxel with/without bevacizumab in recurrent PROC.

Nicoletta Colombo, MD, PhD, discusses clinical implications for integrating immunotherapy into the treatment arsenal for platinum-resistant ovarian cancer.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in October 2025.

The top 5 OncLive TV videos of the week cover insights in myeloproliferative neoplasms, lung cancer, ovarian cancer, and prostate cancer.

Mirvetuximab soravtansine has received a positive reimbursement recommendation in Canada under the Target Zero initiative for platinum-resistant ovarian cancer.

Kevin Elias, MD, discusses efficacy data from the PRIMA and NOVA trials evaluating niraparib as maintenance therapy in ovarian cancer.

Sarah Lynam, MD, discusses the clinical applicability of mirvetuximab soravtansine and trastuzumab deruxtecan in recurrent ovarian cancer.

Experts reflect on pivotal data, emerging agents, and notable advancements in gynecologic cancer spotlighted during the 2025 ESMO Congress.

Vanda Salutari, MD, discusses the rationale for examining relacorilant plus nab-paclitaxel in PARP inhibitor–treated platinum-resistant ovarian cancer.

Sarah Lynam, MD, details key efficacy data from the phase 2 DESTINY-PanTumor02 trial, evaluating trastuzumab deruxtecan in HER2-expressing solid tumors.